北米のバイオ医薬品市場の2028年までの予測-地域別分析：製品タイプ別、用途別

北米のバイオ医薬品市場は2022年に1,512億2,000万米ドルとなり、2028年には3,157億4,000万米ドルに達すると予測されています。2022年から2028年までのCAGRは13.1%と推定されます。

希少疾患治療の可能性が北米バイオ医薬品市場を牽引

米国国立衛生研究所（NIH）の報告書によると、人口の10%を占める3,000万人の米国人が、7,000種類以上あるとされる希少疾患のいずれかに罹患しています。このような希少疾患の治療薬の開発には、科学的・経営的課題があります。希少疾患に関連する複雑な生物学は、科学者が新薬開発プログラムを設計し実施する上での課題となっています。しかし、このような課題にもかかわらず、北米のバイオ医薬品研究者は、希少疾患治療のための新技術を開発し、画期的な治療法を開発してきました。さらに、過去10年間で、特に治療法がない、あるいは治療選択肢が限られている疾患に対して、350の希少疾病用医薬品が米国食品医薬品局（USFDA）により承認されています。トランスサイレチン型アミロイド心筋症（ATTR-CM）は、浸潤性心筋症を引き起こす心臓の機能異常を特徴とする、生命を脅かす進行性の心血管希少疾患です。一度診断されると、未治療の場合、平均余命はわずか2.5～3.5年です。さらに、バイオ医薬品会社であるウルトラジェニックス・ファーマシューティカル社は、重篤な希少超遺伝性疾患であるグリコーゲン貯蔵症（GSD）3型の治療薬として開発された分子の安全性試験と投与量の決定に従事しています。同社は2021年12月にUX053の臨床試験を開始し、GSD3型患者を治療する最初の医薬品として上市を目指しています。UX053のmRNAは、大きな遺伝子を標的細胞に送達し、タンパク質の均一な発現を実現することができます。同社は、投与レベルや投与回数を調整することにより、患者一人ひとりのニーズに応じてmRNA治療を個別化する計画です。このような臨床開発、上市、承認が北米バイオ医薬品市場の拡大を加速させています。

北米バイオ医薬品市場概要

北米バイオ医薬品市場は米国、カナダ、メキシコに区分されます。この地域の市場成長は、がん罹患率の増加、同地域での製品導入の増加、バイオ医薬品の技術進歩に起因しています。バイオ医薬品産業は、アルツハイマー病、がん、心臓病、C型肝炎など、高コストで衰弱しやすい病気の治療に革命を起こす大きな可能性を秘めた、医学研究において極めて重要な段階にあります。バイオ医薬品産業は米国経済に重要な貢献をしています。米国はほとんどの研究開発投資とイノベーション指標で世界をリードしています。2020年現在、米国のバイオ医薬品企業は3,400以上の医薬品を臨床開発しており、全世界の推定医薬品数8,000のほぼ半分を占めている（うち1,100は各種がんの治療薬として開発中）。バイオ医薬品産業は、直接的な経済活動を生み出し、間接的な活動を支えることで、米国経済に重要な貢献をしています。医薬品・医療品製造業は、2018年の民間部門付加価値の0.95％を占めました。バイオテクノロジー研究開発施設はさらに0.23%を占めています。2022年7月に更新された米国疾病予防管理センター（CDC）のデータによると、冠動脈疾患は心臓病の中で最も一般的な疾患です。米国では20歳以上の成人約2,010万人がこの疾患に苦しんでいます。CDCのデータによると、40秒に1人が心臓発作を起こし、米国では年間80万5,000人近くが心臓発作に苦しんでいます。これらすべての要因が、予測期間中に北米バイオ医薬品市場の成長を大きく押し上げると予想されます。

北米バイオ医薬品市場の収益と2028年までの予測（10億米ドル）

北米バイオ医薬品市場のセグメンテーション

北米のバイオ医薬品市場は、製品タイプ、用途、国に区分されます。

製品タイプ別に見ると、北米のバイオ医薬品市場は、モノクローナル抗体、組み換えワクチン、従来型ワクチン、組み換え成長因子、精製タンパク質、組み換えタンパク質、組み換えホルモン、組み換え酵素、細胞・遺伝子治療、サイトカイン・インターフェロン・インターロイキン、その他に区分されます。2022年には、モノクローナル抗体分野が北米バイオ医薬品市場で最大のシェアを占めました。

組み換えワクチン分野はさらに、がんワクチン、マラリアワクチン、エボラワクチン、B型肝炎ワクチン、破傷風ワクチン、ジフテリアワクチン、コレラワクチン、その他に区分されます。従来型ワクチン分野は、さらにポリオワクチン、ポックスワクチン、その他に細分化されます。組換え成長因子セグメントはさらにエリスロポエチン、顆粒球コロニー刺激因子に細分化されます。精製タンパク質セグメントはさらに白血病抑制因子（LIF）、P53タンパク質、P38タンパク質、その他に細分化されます。組換えタンパク質セグメントは、さらに血清アルブミン、アミロイドタンパク質、ディフェンシン、トランスフェリンにセグメント化されます。遺伝子組換えホルモンは、さらに遺伝子組換えヒト成長ホルモン、遺伝子組換えインスリン、その他の遺伝子組換えホルモンに区分されます。組換え酵素セグメントはさらに、エンテロキナーゼ、シクラーゼ、カスパーゼ、カテプシンに細分化されます。細胞・遺伝子治療分野はさらに、同種製品、自家製品、無細胞製品に区分されます。

用途別では、北米のバイオ医薬品市場は、がん、炎症・感染症、自己免疫疾患、代謝疾患、ホルモン疾患・成長不全、心血管疾患、神経疾患、その他に区分されます。2022年、北米のバイオ医薬品市場で最大のシェアを占めたのはがん領域でした。

国別に見ると、北米バイオ医薬品市場は米国、カナダ、メキシコに区分されます。2022年には、米国が北米バイオ医薬品市場で最大のシェアを占めました。

AbbVie Inc、AGC Biologics AS、Amgen Inc、Boehringer Ingelheim International GmbH、Bristol-Myers Squibb Co、Eli Lilly and Co、Johnson &Johnson、Lonza Group AG、Thermo Fisher Scientific Inc、WuXi Biologics Incが北米バイオ医薬品市場で事業を展開する大手企業です。

目次

第1章 イントロダクション

第2章 北米バイオ医薬品市場-要点

第3章 調査手法

• 調査範囲
• 2次調査
• 1次調査

第4章 北米バイオ医薬品市場情勢

• 概観
• 北米PEST分析
• 専門家の見解

第5章 北米バイオ医薬品市場- 主要市場力学

• 市場促進要因
  • がん治療薬への応用拡大
  • 希少疾患治療の可能性
• 市場抑制要因
  • 製造インフラの高コスト
• 市場機会
  • 臨床試験の加速
• 今後の動向
  • バイオ医薬品の受託製造
• 影響分析

第6章 バイオ医薬品市場：北米分析

• 北米バイオ医薬品市場の収益予測と分析

第7章 北米バイオ医薬品市場- 製品タイプ別収益と2028年までの予測

• 概要
• 北米バイオ医薬品市場2021年・2028年製品タイプ別売上高シェア（%）
• モノクローナル抗体
• 組み換えワクチン
• 従来型ワクチン
• 組み換え成長因子
• 精製タンパク質
• 組み換えタンパク質
• 組み換えホルモン
• 組み換え酵素
• 細胞および遺伝子治療
• サイトカイン/インターフェロン/インターロイキン
• その他（mRNAベースの治療薬など）

第8章 北米バイオ医薬品市場の分析と2028年までの予測：用途別

• 概要
• 北米のバイオ医薬品市場：用途別、2021年・2028年（%）
• がん領域
• 炎症性疾患および感染性疾患
• 自己免疫疾患
• 代謝疾患
• ホルモン障害と成長不全
• 心血管疾患
• 神経疾患
• その他の治療用途

第9章 北米バイオ医薬品市場：収益と2028年までの予測：国別分析

• 北米
  • 米国
  • カナダ
  • メキシコ

第10章 北米バイオ医薬品市場：業界情勢

• 有機的成長戦略
• 無機的成長戦略

第11章 企業プロファイル

• Amgen Inc
• AbbVie Inc
• Eli Lilly and Co
• Bristol-Myers Squibb Co
• Johnson & Johnson
• Boehringer Ingelheim International GmbH
• Thermo Fisher Scientific Inc
• AGC Biologics AS
• Lonza Group AG
• WuXi Biologics Inc

第12章 付録

List Of Tables

• Table 1. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Table 2. United States Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
• Table 3. United States Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 4. United States Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 5. United States Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
• Table 6. United States Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 7. United States Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 8. United States Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
• Table 9. United States Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
• Table 10. United States Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
• Table 11. United States Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
• Table 12. Canada Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
• Table 13. Canada Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 14. Canada Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 15. Canada Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
• Table 16. Canada Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 17. Canada Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 18. Canada Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
• Table 19. Canada Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
• Table 20. Canada Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
• Table 21. Canada Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
• Table 22. Mexico Biopharmaceuticals Market, by Product Type - Revenue and Forecast to 2028 (US$ Million)
• Table 23. Mexico Biopharmaceuticals Market, by Recombinant Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 24. Mexico Biopharmaceuticals Market, by Conventional Vaccines - Revenue and Forecast to 2028 (US$ Million)
• Table 25. Mexico Biopharmaceuticals Market, by Recombinant Growth Factors - Revenue and Forecast to 2028 (US$ Million)
• Table 26. Mexico Biopharmaceuticals Market, by Purified Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 27. Mexico Biopharmaceuticals Market, by Recombinant Proteins - Revenue and Forecast to 2028 (US$ Million)
• Table 28. Mexico Biopharmaceuticals Market, by Recombinant Hormones - Revenue and Forecast to 2028 (US$ Million)
• Table 29. Mexico Biopharmaceuticals Market, by Recombinant Enzymes - Revenue and Forecast to 2028 (US$ Million)
• Table 30. Mexico Biopharmaceuticals Market, by Cell & Gene Therapies - Revenue and Forecast to 2028 (US$ Million)
• Table 31. Mexico Biopharmaceuticals Market, by Application - Revenue and Forecast to 2028 (US$ Million)
• Table 32. Recent Organic Growth Strategies in Biopharmaceuticals Market
• Table 33. Recent Inorganic Growth Strategies in the North America biopharmaceuticals market
• Table 34. Glossary of Terms

List Of Figures

• Figure 1. North America Biopharmaceuticals Market Segmentation
• Figure 2. North America Biopharmaceuticals Market, by Country
• Figure 3. North America Biopharmaceuticals Market Overview
• Figure 4. Monoclonal Antibodies Segment Held Largest Share of Product Type Segment in North America Biopharmaceuticals Market
• Figure 5. US Expected to Show Remarkable Growth During Forecast Period
• Figure 6. North America: PEST Analysis
• Figure 7. Experts\' Opinion
• Figure 8. North America Biopharmaceuticals Market: Impact Analysis of Drivers and Restraints
• Figure 9. North America Biopharmaceuticals Market - Revenue Forecast and Analysis - 2020-2028
• Figure 10. North America Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
• Figure 11. Monoclonal Antibodies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 12. Recombinant Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 13. Cancer Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 14. Malaria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 15. Ebola Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 16. Hepatitis-B Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 17. Tetanus Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 18. Diphtheria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 19. Cholera Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 20. Others: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 21. Conventional Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 22. Polio Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 23. Pox Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 24. Other Conventional Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 25. Recombinant Growth Factors: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 26. Erythropoietin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 27. Granulocyte Colony Stimulating Factor: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 28. Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 29. Leukemia Inhibitory Factor (LIF): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 30. P53 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 31. P38 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 32. Other Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 33. Recombinant Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 34. Serum Albumin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 35. Amyloid Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 36. Defensin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 37. Transferrin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 38. Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 39. Recombinant Human Growth Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 40. Recombinant Insulin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 41. Other Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 42. Recombinant Enzymes: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 43. Enterokinase: north America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 44. Cyclase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 45. Caspase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 46. Cathepsin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 47. Cell and Gene Therapies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 48. Allogenic Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 49. Autologous Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 50. Acellular Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 51. Cytokines/Interferon/Interleukins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 52. Others (mRNA Based Therapeutics, etc.): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 53. North America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
• Figure 54. Oncology: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 55. Inflammatory and Infectious Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 56. Autoimmune Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 57. Metabolic Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 58. Hormonal Disorders and Growth Failure: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 59. Cardiovascular Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 60. Neurological Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 61. Other Therapeutic Applications: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 62. North America: Biopharmaceuticals Market, by Key Country - Revenue (2021) (US$ Million)
• Figure 63. North America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
• Figure 64. United States: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 65. Canada: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• Figure 66. Mexico: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

The North America biopharmaceuticals market was valued at US$ 151.22 billion in 2022 and is expected to reach US$ 315.74 billion by 2028. It is estimated to register a CAGR of 13.1% from 2022 to 2028.

Potential to Treat Rare Diseases Drives North America Biopharmaceuticals Market

According to the National Institute of Health (NIH) report, 30 million Americans, accounting for 10% of the population, have one of the ~7,000 known rare diseases. Developing medicines for treating these rare diseases presents both scientific and operational challenges. Complex biology associated with rare diseases presents challenges for scientists to design and implement new drug development programs. However, despite these challenges, biopharmaceutical researchers in the North America have developed new technologies for treating rare diseases and developing groundbreaking therapies. Moreover, in the last decade, 350 orphan drugs have been approved by USFDA, particularly for conditions lacking treatment or having limited treatment options. Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive cardiovascular rare disease characterized by the abnormal functioning of the heart, causing infiltrative cardiomyopathy. Once diagnosed, the median life expectancy is only ~2.5-3.5 years if left untreated. Further, biopharmaceuticals company Ultragenyx Pharmaceutical Inc. is engaged in the safety testing and dosage determination of molecules developed to treat Glycogen Storage Disease (GSD) type 3, a serious rare and ultra-genetic disease. The company initiated the clinical studies of UX053 in December 2021 to launch it as the first potential medicine for treating patients living with GSD3. The UX053 mRNA can deliver large genes to targeted cells for achieving a high uniformity of protein expression. The company plans to individualize mRNA therapies based on the needs of each patient through the adjustment of dose levels and frequency. Such clinical developments, launches, and approvals are accelerating the North America biopharmaceuticals market expansion.

North America Biopharmaceuticals Market Overview

The North America biopharmaceuticals market is segmented into the US, Canada, and Mexico. The market growth in this region is attributed to the increasing incidence of cancer, growing product introduction in the region, and technological advancements in biopharmaceuticals. The biopharmaceuticals industry is at a pivotal stage in medical research with tremendous potential to further revolutionize the treatment of costly and debilitating diseases such as Alzheimer's, cancer, heart disease, and hepatitis C. The rising burden of chronic diseases and increased investment in research and development activities in the US are driving the market in the region. The biopharmaceuticals industry makes important contributions to the US economy. The US leads the world in most R&D investment and innovation indices. As of 2020, biopharmaceutical companies in the United States have more than 3,400 drugs in clinical development, accounting for almost half of the estimated 8,000 drugs worldwide (of which 1,100 are being developed to treat various types of cancer). The biopharmaceuticals industry makes important contributions to the US economy by creating direct economic activities and supporting indirect activities. Pharmaceutical and medical manufacturing accounted for 0.95% of private sector value added in 2018. Biotech R&D facilities accounted for another 0.23%. Data from the Centers for Disease Control and Prevention (CDC), updated in July 2022, shows that coronary artery disease is the most common form of heart disease. Approximately 20.1 million adults aged 20 and older in the United States suffer from this condition. According to CDC data, someone suffers a heart attack every 40 seconds, and nearly 805,000 people in the US suffer a heart attack annually. All these factors are expected to boost the North America biopharmaceuticals market growth significantly during the forecast period.

North America Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Billion)

North America Biopharmaceuticals Market Segmentation

The North America biopharmaceuticals market is segmented into product type, application, and country.

Based on product type, the North America biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the North America biopharmaceuticals market.

The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, Ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.

Based on application, the North America biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the North America biopharmaceuticals market.

Based on country, the North America biopharmaceuticals market is segmented into the US, Canada, and Mexico. In 2022, the US accounted for the largest share of the North America biopharmaceuticals market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, Thermo Fisher Scientific Inc, and WuXi Biologics Inc are the leading companies operating in the North America biopharmaceuticals market.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America biopharmaceutical market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the North America biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
• develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth North America market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

• 1.1 Scope of the Study
• 1.2 The Insight Partners Research Report Guidance
• 1.3 Market Segmentation
  • 1.3.1 North America Biopharmaceuticals Market - by Product Type
  • 1.3.2 North America Biopharmaceuticals Market - by Application
  • 1.3.3 North America Biopharmaceuticals Market - by Country

2. North America Biopharmaceuticals Market - Key Takeaways

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. North America Biopharmaceuticals Market - Market Landscape

• 4.1 Overview
• 4.2 North America PEST Analysis
• 4.3 Expert's Opinion

5. North America Biopharmaceuticals Market - Key Market Dynamics

• 5.1 Market Drivers
  • 5.1.1 Rising Application in Cancer Therapeutics
  • 5.1.2 Potential to Treat Rare Diseases
• 5.2 Market Restraints
  • 5.2.1 High Cost of Manufacturing Infrastructure
• 5.3 Market Opportunities
  • 5.3.1 Accelerated Clinical Trials
• 5.4 Future Trends
  • 5.4.1 Contract Manufacturing of Biopharmaceuticals
• 5.5 Impact Analysis

6. Biopharmaceuticals Market - North America Analysis

• 6.1 North America Biopharmaceuticals Market Revenue Forecast and Analysis

7. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 - by Product Type

• 7.1 Overview
• 7.2 North America Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
• 7.3 Monoclonal Antibodies
  • 7.3.1 Overview
  • 7.3.2 Monoclonal Antibodies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.4 Recombinant Vaccines
  • 7.4.1 Overview
  • 7.4.2 Recombinant Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.1 Cancer Vaccine
      • 7.4.2.1.1 Overview
      • 7.4.2.1.2 Cancer Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.2 Malaria Vaccine
      • 7.4.2.2.1 Overview
      • 7.4.2.2.2 Malaria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.3 Ebola Vaccine
      • 7.4.2.3.1 Overview
      • 7.4.2.3.2 Ebola Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.4 Hepatitis-B Vaccine
      • 7.4.2.4.1 Overview
      • 7.4.2.4.2 Hepatitis-B Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.5 Tetanus Vaccine
      • 7.4.2.5.1 Overview
      • 7.4.2.5.2 Tetanus Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.6 Diphtheria Vaccine
      • 7.4.2.6.1 Overview
      • 7.4.2.6.2 Diphtheria Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.7 Cholera Vaccine
      • 7.4.2.7.1 Overview
      • 7.4.2.7.2 Cholera Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.4.2.8 Others
      • 7.4.2.8.1 Overview
      • 7.4.2.8.2 Others: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.5 Conventional Vaccines
  • 7.5.1 Overview
  • 7.5.2 Conventional Vaccines: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.5.2.1 Polio Vaccine
      • 7.5.2.1.1 Overview
      • 7.5.2.1.2 Polio Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.5.2.2 Pox Vaccine
      • 7.5.2.2.1 Overview
      • 7.5.2.2.2 Pox Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.5.2.3 Other Conventional Vaccine
      • 7.5.2.3.1 Overview
      • 7.5.2.3.2 Other Conventional Vaccine: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.6 Recombinant Growth Factors
  • 7.6.1 Overview
  • 7.6.2 Recombinant Growth Factors: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.6.2.1 Erythropoietin
      • 7.6.2.1.1 Overview
      • 7.6.2.1.2 Erythropoietin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.6.2.2 Granulocyte Colony Stimulating Factor
      • 7.6.2.2.1 Overview
      • 7.6.2.2.2 Granulocyte Colony Stimulating Factor: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.7 Purified Proteins
  • 7.7.1 Overview
  • 7.7.2 Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.7.2.1 Leukemia Inhibitory Factor (LIF)
      • 7.7.2.1.1 Overview
      • 7.7.2.1.2 Leukemia Inhibitory Factor (LIF): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.7.2.2 P53 Protein
      • 7.7.2.2.1 Overview
      • 7.7.2.2.2 P53 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.7.2.3 P38 Protein
      • 7.7.2.3.1 Overview
      • 7.7.2.3.2 P38 Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.7.2.4 Other Purified Proteins
      • 7.7.2.4.1 Overview
      • 7.7.2.4.2 Other Purified Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.8 Recombinant Proteins
  • 7.8.1 Overview
  • 7.8.2 Recombinant Proteins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.8.2.1 Serum Albumin
      • 7.8.2.1.1 Overview
      • 7.8.2.1.2 Serum Albumin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.8.2.2 Amyloid Protein
      • 7.8.2.2.1 Overview
      • 7.8.2.2.2 Amyloid Protein: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.8.2.3 Defensin
      • 7.8.2.3.1 Overview
      • 7.8.2.3.2 Defensin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.8.2.4 Transferrin
      • 7.8.2.4.1 Overview
      • 7.8.2.4.2 Transferrin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.9 Recombinant Hormones
  • 7.9.1 Overview
  • 7.9.2 Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.9.2.1 Recombinant Human Growth Hormones
      • 7.9.2.1.1 Overview
      • 7.9.2.1.2 Recombinant Human Growth Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.9.2.2 Recombinant Insulin
      • 7.9.2.2.1 Overview
      • 7.9.2.2.2 Recombinant Insulin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.9.2.3 Other Recombinant Hormones
      • 7.9.2.3.1 Overview
      • 7.9.2.3.2 Other Recombinant Hormones: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.10 Recombinant Enzymes
  • 7.10.1 Overview
  • 7.10.2 Recombinant Enzymes: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.10.2.1 Enterokinase
      • 7.10.2.1.1 Overview
      • 7.10.2.1.2 Enterokinase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.10.2.2 Cyclase
      • 7.10.2.2.1 Overview
      • 7.10.2.2.2 Cyclase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.10.2.3 Caspase
      • 7.10.2.3.1 Overview
      • 7.10.2.3.2 Caspase: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.10.2.4 Cathepsin
      • 7.10.2.4.1 Overview
      • 7.10.2.4.2 Cathepsin: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.11 Cell and Gene Therapies
  • 7.11.1 Overview
  • 7.11.2 Cell and Gene Therapies: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.11.2.1 Allogenic Products
      • 7.11.2.1.1 Overview
      • 7.11.2.1.2 Allogenic Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.11.2.2 Autologous Products
      • 7.11.2.2.1 Overview
      • 7.11.2.2.2 Autologous Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
    • 7.11.2.3 Acellular Products
      • 7.11.2.3.1 Overview
      • 7.11.2.3.2 Acellular Products: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.12 Cytokines/Interferon/Interleukins
  • 7.12.1 Overview
  • 7.12.2 Cytokines/Interferon/Interleukins: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 7.13 Others (mRNA Based Therapeutics, etc.)
  • 7.13.1 Overview
  • 7.13.2 Others (mRNA Based Therapeutics, etc.): North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

8. North America Biopharmaceuticals Market Analysis and Forecasts to 2028 - by Application

• 8.1 Overview
• 8.2 North America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
• 8.3 Oncology
  • 8.3.1 Overview
  • 8.3.2 Oncology: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.4 Inflammatory and Infectious Diseases
  • 8.4.1 Overview
  • 8.4.2 Inflammatory and Infectious Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.5 Autoimmune Disorders
  • 8.5.1 Overview
  • 8.5.2 Autoimmune Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.6 Metabolic Disorders
  • 8.6.1 Overview
  • 8.6.2 Metabolic Disorders: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.7 Hormonal Disorders and Growth Failure
  • 8.7.1 Overview
  • 8.7.2 Hormonal Disorders and Growth Failure: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.8 Cardiovascular Diseases
  • 8.8.1 Overview
  • 8.8.2 Cardiovascular Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.9 Neurological Diseases
  • 8.9.1 Overview
  • 8.9.2 Neurological Diseases: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
• 8.10 Other Therapeutic Applications
  • 8.10.1 Overview
  • 8.10.2 Other Therapeutic Applications: North America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

9. North America Biopharmaceuticals Market - Revenue and Forecast to 2028 - Country Analysis

• 9.1 Overview
  • 9.1.1 North America: Biopharmaceuticals Market, by Country
    • 9.1.1.1 United States: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 9.1.1.1.1 United States: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
      • 9.1.1.1.1.1 United States: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.1.1.2 United States: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.1.1.3 United States: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
      • 9.1.1.1.1.4 United States: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
      • 9.1.1.1.1.5 United States: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
      • 9.1.1.1.1.6 United States: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
      • 9.1.1.1.1.7 United States: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
      • 9.1.1.1.1.8 United States: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
      • 9.1.1.1.2 United States: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
    • 9.1.1.2 Canada: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 9.1.1.2.1 Canada: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
      • 9.1.1.2.1.1 Canada: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.2.1.2 Canada: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.2.1.3 Canada: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
      • 9.1.1.2.1.4 Canada: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
      • 9.1.1.2.1.5 Canada: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
      • 9.1.1.2.1.6 Canada: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
      • 9.1.1.2.1.7 Canada: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
      • 9.1.1.2.1.8 Canada: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
      • 9.1.1.2.2 Canada: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
    • 9.1.1.3 Mexico: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 9.1.1.3.1 Mexico: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
      • 9.1.1.3.1.1 Mexico: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.3.1.2 Mexico: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
      • 9.1.1.3.1.3 Mexico: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
      • 9.1.1.3.1.4 Mexico: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
      • 9.1.1.3.1.5 Mexico: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
      • 9.1.1.3.1.6 Mexico: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
      • 9.1.1.3.1.7 Mexico: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
      • 9.1.1.3.1.8 Mexico: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
      • 9.1.1.3.2 Mexico: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)

10. North America Biopharmaceuticals Market - Industry Landscape

• 10.1 Overview
• 10.2 Organic Growth Strategies
  • 10.2.1 Overview
• 10.3 Inorganic Growth Strategies
  • 10.3.1 Overview

11. Company Profiles

• 11.1 Amgen Inc
  • 11.1.1 Key Facts
  • 11.1.2 Business Description
  • 11.1.3 Products and Services
  • 11.1.4 Financial Overview
  • 11.1.5 SWOT Analysis
  • 11.1.6 Key Developments
• 11.2 AbbVie Inc
  • 11.2.1 Key Facts
  • 11.2.2 Business Description
  • 11.2.3 Products and Services
  • 11.2.4 Financial Overview
  • 11.2.5 SWOT Analysis
  • 11.2.6 Key Developments
• 11.3 Eli Lilly and Co
  • 11.3.1 Key Facts
  • 11.3.2 Business Description
  • 11.3.3 Products and Services
  • 11.3.4 Financial Overview
  • 11.3.5 SWOT Analysis
  • 11.3.6 Key Developments
• 11.4 Bristol-Myers Squibb Co
  • 11.4.1 Key Facts
  • 11.4.2 Business Description
  • 11.4.3 Products and Services
  • 11.4.4 Financial Overview
  • 11.4.5 SWOT Analysis
  • 11.4.6 Key Developments
• 11.5 Johnson & Johnson
  • 11.5.1 Key Facts
  • 11.5.2 Business Description
  • 11.5.3 Products and Services
  • 11.5.4 Financial Overview
  • 11.5.5 SWOT Analysis
  • 11.5.6 Key Developments
• 11.6 Boehringer Ingelheim International GmbH
  • 11.6.1 Key Facts
  • 11.6.2 Business Description
  • 11.6.3 Products and Services
  • 11.6.4 Financial Overview
  • 11.6.5 SWOT Analysis
  • 11.6.6 Key Developments
• 11.7 Thermo Fisher Scientific Inc
  • 11.7.1 Key Facts
  • 11.7.2 Business Description
  • 11.7.3 Products and Services
  • 11.7.4 Financial Overview
  • 11.7.5 SWOT Analysis
  • 11.7.6 Key Developments
• 11.8 AGC Biologics AS
  • 11.8.1 Key Facts
  • 11.8.2 Business Description
  • 11.8.3 Products and Services
  • 11.8.4 Financial Overview
  • 11.8.5 SWOT Analysis
  • 11.8.6 Key Developments
• 11.9 Lonza Group AG
  • 11.9.1 Key Facts
  • 11.9.2 Business Description
  • 11.9.3 Products and Services
  • 11.9.4 Financial Overview
  • 11.9.5 SWOT Analysis
  • 11.9.6 Key Developments
• 11.10 WuXi Biologics Inc
  • 11.10.1 Key Facts
  • 11.10.2 Business Description
  • 11.10.3 Products and Services
  • 11.10.4 Financial Overview
  • 11.10.5 SWOT Analysis
  • 11.10.6 Key Developments

12. Appendix

• 12.1 About The Insight Partners
• 12.2 Glossary of Terms